CLOs on the Move


 
Maxor is a leading pharmacy care solutions company dedicated to improving patient outcomes and lowering the total cost of care through our clinically integrated set of pharmacy care services. Our teams help optimize the pharmacy experience for patients, our customers, their employees, and members whether it`s through our customized pharmacy benefit offerings; providing access to prescription medications and therapies through our home delivery and specialty pharmacies; or delivering clinical and financial value with our end-to-end pharmacy management solutions. With a legacy of exceptional service and deep clinical and pharmacy expertise, Maxor has been a trusted partner enabling pharmacy care since ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.maxor.com
  • 320 South Polk Street Suite 200
    Amarillo, TX USA 79101
  • Phone: 800.658.6146

Executives

Name Title Contact Details
Jessica Lee
Chief Compliance and Ethics Officer Profile
Leah Bailey
General Counsel Profile

Similar Companies

EIS Analytics

EIS Analytics is a Vancouver, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Grove Hill Memorial Hospital Inc

Grove Hill Memorial Hospital Inc is a Grove Hill, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Eden Communications Group

Eden developed a unique onsite depression-and-anxiety-reduction program that took a novel approach of turning employers into educators. We created a turnkey kit employers could use to lead worksite seminars that educate employees about depression and

Cummins, MacFail and Nutry

Cummins, MacFail & Nutry is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.